
On Thursday, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends the approval of Covid-19 developed by Pfizer and Biontech for use in children aged 5 to 11 years.
The extended indication of the vaccine, which is known as Comirnaty, will still need to be officially approved by the European Commission before children as young as 5 can receive their first shots. This approval, however, is typically considered a mere formality.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app